Resuscitative Endocrinology: Single-dose Clinical Uses for Estrogen - Traumatic Hemorrhagic Shock (RESCUE - Shock) (RESCUE - Shock)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00973102
Recruitment Status : Completed
First Posted : September 9, 2009
Last Update Posted : May 1, 2014
University of Washington
Resuscitation Outcomes Consortium
Information provided by (Responsible Party):
University of Texas Southwestern Medical Center

Brief Summary:

Annually in the United States, approximately 30 million people require treatment for traumatic injuries in emergency departments. Two million of these patients require hospitalization, with several hundred thousand ultimately dying, often due to extreme blood loss. Importantly, these traumatic injuries are the leading cause of death and disability for children and young adults under the age of 44, with the total cost of trauma in the U.S. approaching $260 billion each year.

Despite advances in pre-hospital care, early resuscitation, surgical interventions and intensive care monitoring aimed at the primary traumatic injury, many survivors never recover. A significant cause of this mortality and morbidity is thought due to potentially preventable secondary injury, namely oxidant injury, inflammation, and apoptosis beginning in the first few hours after the severe traumatic event.

In spite of the current bleak outlook for many of these patients, a series of animal investigations have uncovered a promising solution to the problem of the secondary injury seen in hemorrhagic shock and other similar processes, namely the early administration of estrogen, a strong anti-oxidant, anti-inflammatory and anti-apoptotic compound. Based on these encouraging results from animal studies, the investigators hypothesize that early administration of IV Premarin® in patients with hemorrhagic shock will safely reduce secondary injury, and improve survival.

Condition or disease Intervention/treatment Phase
Hemorrhagic Shock Drug: Premarin IV Drug: Placebo Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Resuscitative Endocrinology: Single-dose Clinical Uses for Estrogen - Traumatic Hemorrhagic Shock (RESCUE - Shock): A Phase II Trial to Evaluate the Effects of A Single Dose of Intravenous Premarin for the Treatment of Patients With Hemorrhagic Shock
Study Start Date : July 2009
Actual Primary Completion Date : January 2012
Actual Study Completion Date : May 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Shock

Arm Intervention/treatment
Experimental: Premarin IV Drug: Premarin IV
One time dose of Premarin IV
Other Name: Estrogen IV

Placebo Comparator: Placebo Drug: Placebo
One time dose of placebo.

Primary Outcome Measures :
  1. Survival [ Time Frame: 28 Days ]

Secondary Outcome Measures :
  1. Examine effects of IV estrogen vs. placebo in patients with traumatic hemorrhagic shock: Mortality; levels of injury markers & sex steroids; Glasgow Outcomes Scale (GOSE), DRS, cognitive, neurological & functional outcomes in those with TBI; safety [ Time Frame: Up to 6 months post-injury ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age≥ 18 yrs or < 50 yrs
  2. Blunt or penetrating trauma leading to presumed hemorrhagic shock
  3. Pre-hospital or ED systolic blood pressure < 90
  4. Receiving medical treatment in the Emergency Department (ED) of Parkland Hospital or Baylor University Medical Center Emergency Department, Level I Trauma Centers in Dallas, Texas

Exclusion Criteria:

  1. Those who would receive the study drug > 120 minutes after the traumatic event
  2. Time of injury is unknown
  3. Known indication for IV estrogen
  4. Known contraindication for estrogen
  5. Estimated age <18 or > 50 years
  6. Cardiopulmonary Resuscitation (CPR) prior to randomization
  7. Known incarceration
  8. Severe hypothermia (suspected T < 28° C)
  9. Drowning or asphyxia due to hanging
  10. Burns TBSA > 20%
  11. Isolated penetrating injury to the head
  12. Known inclusion in another interventional trial related to this traumatic event prior to randomization
  13. Known legal do not resuscitate (DNR) orders in place prior to randomization
  14. Recognized spinal cord injury prior to study drug administration

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00973102

United States, Texas
Parkland Hospital
Dallas, Texas, United States, 75235
Baylor University Medical Center
Dallas, Texas, United States, 75246
Sponsors and Collaborators
University of Texas Southwestern Medical Center
University of Washington
Resuscitation Outcomes Consortium

Responsible Party: University of Texas Southwestern Medical Center Identifier: NCT00973102     History of Changes
Other Study ID Numbers: RESCUE - Shock
First Posted: September 9, 2009    Key Record Dates
Last Update Posted: May 1, 2014
Last Verified: April 2014

Additional relevant MeSH terms:
Shock, Hemorrhagic
Pathologic Processes
Estrogens, Conjugated (USP)
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs